Search

Displaying results 1031 - 1040 of 7554 in total
  1. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    It was developed by The Medicines Company (acquired by Novartis). … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.

  2. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients. … [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]

  3. Drug

    Coagulation Factor IX Human

    go.drugbank.com/drugs/DB13152
    ApprovedInvestigational

    Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  4. Drug

    Cefuroxime

    go.drugbank.com/drugs/DB01112
    ApprovedInvestigational

    Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.

    Products: Nu-cefuroxime
  5. Drug

    Ceftazidime

    go.drugbank.com/drugs/DB00438
    ApprovedInvestigational

    [L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of

  6. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

  7. Drug

    Cholestyramine

    go.drugbank.com/drugs/DB01432
    ApprovedInvestigational

    Cholestyramine resin is quite hydrophilic, but insoluble in water.

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  8. Drug

    Human Rho(D) immune globulin

    go.drugbank.com/drugs/DB11597
    Approved

    Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). … It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults.

  9. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).

  10. Drug

    Sodium glycerophosphate

    go.drugbank.com/drugs/DB09561
    Approved

    It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. … The extent of this reaction is dependent on the activity of serum alkaline phosphatases.

    Mixtures: OLICLINOMEL N4-550 E EMULSION FOR INFUSION, OLICLINOMEL N7-1000 E EMULSION FOR INFUSION